Robot Assisted Laparoscopic Adrenalectomy: Does Size Matter?

minimally invasive surgery outcomes robotic adrenalectomy tumor size

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
20 Aug 2020
Historique:
entrez: 24 9 2020
pubmed: 25 9 2020
medline: 25 9 2020
Statut: epublish

Résumé

 Open adrenalectomy (OA) is considered to be the standard care for large adrenal tumors. Minimally invasive surgery (MIS) using laparoscopic technique is considered for many patients in the modern era. Robot assisted laparoscopic adrenalectomy (RALA) can be an extremely useful tool which will negate the disadvantage of laparoscopic method. The aim of the present study is to determine whether adrenal tumor size and laterality have an impact on patients undergoing RALA with respect to perioperative and postoperative outcomes.  Methods: During the study period, 38 patients who underwent RALA in a tertiary care center were considered for retrospectively analysis. The study populations were subdivided into distinctive groups based on the tumor size (<5 cm and ≥5 cm, <8 cm and ≥8 cm), and side (right and left side). For all the subgroups, perioperative and postoperative outcomes were analyzed. Perioperative and postoperative outcomes were assessed between patient groups, group a) <5 cm and ≥5 cm tumor, group b) <8 cm and ≥8 cm, and group c) laterality (right vs left).  None of the patients showed any differences. In the current study, the conversion rate, readmission, and mortality were not observed. No major complications were noted.  RALA appears to be an extremely viable alternative to MIS using laparoscopic technique. The operative time, console time, blood loss, complication rates, and stay were extremely minimal irrespective of the size or laterality of the adrenal tumor.

Identifiants

pubmed: 32968553
doi: 10.7759/cureus.9887
pmc: PMC7502421
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e9887

Informations de copyright

Copyright © 2020, Ragavan et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Ann Surg Oncol. 2013 Dec;20(13):4190-4
pubmed: 23864309
Surg Endosc. 2016 Aug;30(8):3532-40
pubmed: 26541739
J Laparoendosc Adv Surg Tech A. 2001 Dec;11(6):415-9
pubmed: 11814134
Investig Clin Urol. 2016 Dec;57(Suppl 2):S130-S146
pubmed: 27995217
Eur Urol. 2014 Nov;66(5):898-905
pubmed: 24830625
Kaohsiung J Med Sci. 2009 Aug;25(8):438-44
pubmed: 19605338
Br J Surg. 2005 Jun;92(6):719-23
pubmed: 15856491
Surg Laparosc Endosc Percutan Tech. 2011 Aug;21(4):248-54
pubmed: 21857473
J Laparoendosc Adv Surg Tech A. 2019 Jan;29(1):19-23
pubmed: 30265584
Ann Surg Oncol. 2012 Jul;19(7):2288-94
pubmed: 22396002
J Endourol. 2007 Nov;21(11):1333-7
pubmed: 18042025
Int J Med Robot. 2013 Sep;9(3):345-50
pubmed: 23640899
JSLS. 2010 Jul-Sep;14(3):369-73
pubmed: 21333190
Langenbecks Arch Surg. 2016 Nov;401(7):999-1006
pubmed: 27516077
Int J Surg. 2015 Dec;24(Pt A):75-80
pubmed: 26542988
J Robot Surg. 2018 Sep;12(3):553-555
pubmed: 28748502
J Visc Surg. 2011 Sep;148(4):e250-61
pubmed: 21820984
Urology. 2008 Jun;71(6):1138-41
pubmed: 18336879
Curr Opin Endocrinol Diabetes Obes. 2011 Jun;18(3):193-7
pubmed: 21494137

Auteurs

Narasimhan Ragavan (N)

Urology, Apollo Hospitals, Chennai, IND.

Nivash Selvaraj (N)

Urology, Apollo Hospitals, Chennai, IND.

Deepak Raghavan (D)

Urology, Apollo Hospitals, Chennai, IND.

Ramesh Kamalakannan (R)

Urology, Apollo Hospitals, Chennai, IND.

Thirumalai Ganesan Govindaswamy (TG)

Urology, Apollo Hospitals, Chennai, IND.

Arun Kumar Balakrishnan (AK)

Urology, Apollo Hospitals, Chennai, IND.

Nitesh Jain (N)

Urology, Apollo Hospitals, Chennai, IND.

Classifications MeSH